Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Amtagvi
product4 mentionslast seen Nov 5, 2026
FDA-approved tumor infiltrating lymphocyte (TIL) therapy for previously treated advanced melanoma.
Relationships 7
- Iovance Biotherapeutics, Inc.developsAmtagvi99% confidence4 sources
- Amtagviapplies toadvanced melanoma treatment99% confidence4 sources
- Iovance Biotherapeutics, Inc.commercializesAmtagvi99% confidence3 sources
- U.S. Food and Drug AdministrationapprovesAmtagvi99% confidence2 sources
- Amtagviapplies tonon-small cell lung cancer treatment90% confidence1 source
- Amtagvicomposed ofpembrolizumab85% confidence1 source
- Amtagvicomposed oflifileucel85% confidence1 source
Relationship
Iovance Biotherapeutics, Inc.developsAmtagvi
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 5, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Iovance Biotherapeutics, Inc. updated its corporate presentation
- filingSEC EDGAROct 29, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
developing and delivering tumor infiltrating lymphocyte (TIL) therapies
- filingSEC EDGAROct 5, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
First and only approved treatment in 2L+ advanced melanoma
- filingSEC EDGARSep 29, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma